Rapid real-time fluorescent PCR gene dosage test for the diagnosis of DNA duplications and deletions.

BACKGROUND Current methods to determine gene dosage are time-consuming and labor-intensive. We describe a new and rapid method to assess gene copy number for identification of DNA duplications or deletions occurring in Charcot-Marie-Tooth disease type 1A (CMT1A) and hereditary neuropathy with liability to pressure palsies (HNPP), respectively. METHODS We studied 16 patients with HNPP, 4 with CMT1A, and 49 control subjects. We used real-time PCR on the LightCycler system with use of a single capillary tube and no post-PCR handling. A polymorphic fragment of the PMP22 gene was amplified to determine gene dosage for heterozygous samples. The presence of two alleles was used to indicate that no deletion was present in HNPP samples. The ratio obtained between the areas under each allele melting curve of heterozygous CMT1A samples was used to determine whether the sequence was duplicated or normal. Homozygous samples required a competitive gene dosage test, where the ratio between the areas under the melting curves of the target DNA of samples and of the competitor molecule was used to determine whether the target sequence was duplicated, deleted, or normal. Samples from HNPP, CMT1A, and controls were analyzed. RESULTS Area ratios were approximately 0.6, 1.0, and 2.0 for HNPP, control, and CMT1A samples, respectively. The results agreed with those obtained by Southern blotting and microsatellite analysis in the same samples. CONCLUSIONS Direct and competitive real-time fluorescent PCR can differentiate one, two, or three copies of the target DNA. The method described is sensitive and accurate for detection of CMT1A duplications and HNPP deletions and is faster and easier than current methods.

[1]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[2]  C. Rochlitz,et al.  Gene dosage by quantitative real-time PCR. , 1999, BioTechniques.

[3]  U. Lass,et al.  LightCycler technology for the quantitation of bcr/abl fusion transcripts. , 1999, Cancer research.

[4]  S. Walker,et al.  Quantitative RT-PCR : Pitfalls and Potential , 1999 .

[5]  J. Landers,et al.  Direct quantitation of RNA transcripts by competitive single-tube RT-PCR and capillary electrophoresis. , 1998, BioTechniques.

[6]  G. Nicholson,et al.  Determination of gene dosage at the PMP22 and androgen receptor loci by quantitative PCR. , 1998, Clinical chemistry.

[7]  E. Ringelstein,et al.  PCR-based strategy for the diagnosis of hereditary neuropathy with liability to pressure palsies and Charcot-Marie-Tooth disease type 1A , 1998, Neurology.

[8]  L. Schöls,et al.  Polymorphisms in the PMP-22 gene region (17p11.2–12) are crucial for simplified diagnosis of duplications/deletions , 1997, Human Genetics.

[9]  L. Shaffer,et al.  Diagnosis of CMT1A duplications and HNPP deletions by interphase FISH: implications for testing in the cytogenetics laboratory. , 1997, American journal of medical genetics.

[10]  J. Mannhalter,et al.  Technical aspects of quantitative competitive PCR. , 1996, BioTechniques.

[11]  J. Lupski.  DNA diagnostics for Charcot-Marie-Tooth disease and related inherited neuropathies. , 1996, Clinical chemistry.

[12]  P. Oefner,et al.  Rapid quantification of gene expression by competitive RT-PCR and ion-pair reversed-phase HPLC. , 1996, BioTechniques.

[13]  A. Aguzzi,et al.  Hypermyelination and demyelinating peripheral neuropathy in Pmp22-deficient mice , 1995, Nature Genetics.

[14]  L. Raeymaekers,et al.  A commentary on the practical applications of competitive PCR. , 1995, Genome research.

[15]  L. Zentilin,et al.  Gene amplification for c-erbB-2, c-myc, epidermal growth factor receptor, int-2, and N-myc measured by quantitative PCR with a multiple competitor template. , 1995, Clinical chemistry.

[16]  D. Le Paslier,et al.  Assignment of microsatellite sequences to the region duplicated in CMT1A (17p12): a useful tool for diagnosis. , 1995, Journal of medical genetics.

[17]  F. Baas,et al.  A frame shift mutation in the PMP22 gene in hereditary neuropathy with liability to pressure palsies , 1994, Nature Genetics.

[18]  J. Lupski,et al.  Inherited primary peripheral neuropathies. Molecular genetics and clinical implications of CMT1A and HNPP. , 1993, JAMA.

[19]  C. Disteche,et al.  DNA deletion associated with hereditary neuropathy with liability to pressure palsies , 1993, Cell.

[20]  L. Zentilin,et al.  A novel procedure for quantitative polymerase chain reaction by coamplification of competitive templates. , 1992, Gene.

[21]  K. Hayasaka,et al.  Localization of PMP-22 gene (candidate gene for the Charcot-Marie-Tooth disease 1a) to band 17p11.2 by direct r-banding fluorescence in situ hybridization , 1992, Japanese Journal of Human Genetics.

[22]  B. Trask,et al.  The gene for the peripheral myelin protein PMP–22 is a candidate for Charcot–Marie–Tooth disease type 1A , 1992, Nature Genetics.

[23]  D. Housman,et al.  The peripheral myelin gene PMP–22/GAS–3 is duplicated in Charcot–Marie–Tooth disease type 1A , 1992, Nature Genetics.

[24]  T. Bird,et al.  Peripheral myelin protein–22 gene maps in the duplication in chromosome 17p11.2 associated with Charcot–Marie–Tooth 1A , 1992, Nature Genetics.

[25]  P. De Jonghe,et al.  The peripheral myelin protein gene PMP–22 is contained within the Charcot–Marie–Tooth disease type 1A duplication , 1992, Nature Genetics.

[26]  D. Ledbetter,et al.  Gene dosage is a mechanism for Charcot-Marie-Tooth disease type 1A , 1992, Nature Genetics.

[27]  F. Baas,et al.  Duplication in chromosome 17p11.2 in Charcot-Marie-Tooth neuropathy type 1a (CMT 1a) , 1991, Neuromuscular Disorders.

[28]  Aravinda Chakravarti,et al.  DNA duplication associated with Charcot-Marie-Tooth disease type 1A , 1991, Cell.

[29]  S. Perrin,et al.  Analysis of cytokine mRNA and DNA: detection and quantitation by competitive polymerase chain reaction. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Kirk M. Ririe,et al.  Fluorescence Monitoring of Rapid Cycle PCR for Quantification , 1998 .

[31]  C. Wittwer,et al.  Continuous fluorescence monitoring of rapid cycle DNA amplification. , 1997, BioTechniques.

[32]  U J Balis,et al.  The LightCycler: a microvolume multisample fluorimeter with rapid temperature control. , 1997, BioTechniques.

[33]  Y. Agid,et al.  Microsatellite mapping of the deletion in patients with hereditary neuropathy with liability to pressure palsies (HNPP): new molecular tools for the study of the region 17p12 --> p11 and for diagnosis. , 1996, Cytogenetics and cell genetics.

[34]  J. Fandrey,et al.  In vivo and in vitro regulation of erythropoietin mRNA: measurement by competitive polymerase chain reaction. , 1993, Blood.